AKEBIA THERAPEUTICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
AKEBIA THERAPEUTICS, INC. (AKBA) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$117.18 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-12.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-12
- AKEBIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$19.44M, a 116.00% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$35.79M, a 282.11% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $38.14M, a 1292.99% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$100.08M.
- AKEBIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$117.18M, a 185.19% decline from fiscal 2016.
- AKEBIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $137.56M, a 709.25% increase from fiscal 2015.
- AKEBIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $17.00M, a 46.98% increase from fiscal 2014.
- AKEBIA THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $11.56M, a 40.92% decline from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 85 month |
|---|---|---|---|---|---|---|---|
| 2017-12-31 | -$19.44M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$55.23M derived: sum of 2 quarters · filed 2018-03-12 | -$17.09M derived: sum of 3 quarters · filed 2018-03-12 | -$117.18M 10-K · filed 2018-03-12 | |||
| 2017-09-30 | -$35.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $2.35M derived: sum of 2 quarters · filed 2017-11-08 | -$97.74M 10-Q · filed 2017-11-08 | $23.77M derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2017-06-30 | $38.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$61.95M 10-Q · filed 2017-08-08 | $59.56M derived: sum of 3 quarters · filed 2018-03-12 | $79.21M derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2017-03-31 | -$100.08M 10-Q · filed 2017-05-09 | $21.42M derived: sum of 2 quarters · filed 2018-03-12 | $41.07M derived: sum of 3 quarters · filed 2018-03-12 | $43.81M derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2016-12-31 | $121.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $141.16M derived: sum of 2 quarters · filed 2018-03-12 | $143.90M derived: sum of 3 quarters · filed 2018-03-12 | $137.56M 10-K · filed 2018-03-12 | |||
| 2016-09-30 | $19.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $22.39M derived: sum of 2 quarters · filed 2017-11-08 | $16.05M 10-Q · filed 2017-11-08 | -$882.00K derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2016-06-30 | $2.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$3.60M 10-Q · filed 2017-08-08 | -$20.54M derived: sum of 3 quarters · filed 2018-03-12 | -$30.07M derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2016-03-31 | -$6.34M 10-Q · filed 2017-05-09 | -$23.27M derived: sum of 2 quarters · filed 2018-03-12 | -$32.81M derived: sum of 3 quarters · filed 2018-03-12 | $15.55M derived: sum of 4 quarters · filed 2018-03-12 | |||
| 2015-12-31 | -$16.93M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$26.47M derived: sum of 2 quarters · filed 2018-03-12 | $21.89M derived: sum of 3 quarters · filed 2018-03-12 | $17.00M 10-K · filed 2018-03-12 | |||
| 2015-09-30 | -$9.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $38.83M derived: sum of 2 quarters · filed 2016-11-09 | $33.93M 10-Q · filed 2016-11-09 | $17.04M derived: sum of 4 quarters · filed 2017-03-06 | |||
| 2015-06-30 | $48.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $43.47M 10-Q · filed 2016-08-08 | $26.58M derived: sum of 3 quarters · filed 2017-03-06 | -$19.15M derived: sum of 4 quarters · filed 2017-03-06 | |||
| 2015-03-31 | -$4.89M 10-Q · filed 2016-05-05 | -$21.78M derived: sum of 2 quarters · filed 2017-03-06 | -$67.51M derived: sum of 3 quarters · filed 2017-03-06 | -$98.43M derived: sum of 4 quarters · filed 2017-03-06 | |||
| 2014-12-31 | -$16.89M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | -$62.61M derived: sum of 2 quarters · filed 2017-03-06 | -$93.54M derived: sum of 3 quarters · filed 2017-03-06 | $11.56M 10-K · filed 2017-03-06 | |||
| 2014-09-30 | -$45.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$76.65M derived: sum of 2 quarters · filed 2015-11-09 | $28.45M 10-Q · filed 2015-11-09 | $25.07M derived: sum of 4 quarters · filed 2016-03-14 | |||
| 2014-06-30 | -$30.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $74.18M 10-Q · filed 2015-08-11 | $74.18M 10-Q · filed 2014-08-11 | $70.79M derived: sum of 3 quarters · filed 2016-03-14 | $54.65M derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2014-03-31 | $105.10M 10-Q · filed 2015-05-11 | $105.10M 10-Q · filed 2014-05-12 | $101.72M derived: sum of 2 quarters · filed 2016-03-14 | $85.58M derived: sum of 3 quarters · filed 2016-03-14 | $123.72M derived: sum of 4 quarters · filed 2016-03-14 | $126.32M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | -$3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$19.53M derived: sum of 2 quarters · filed 2016-03-14 | $18.62M derived: sum of 3 quarters · filed 2016-03-14 | $19.57M 10-K · filed 2016-03-14 | |||
| 2013-09-30 | -$16.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $22.01M derived: sum of 2 quarters · filed 2014-11-10 | $22.96M 10-Q · filed 2014-11-10 | ||||
| 2013-06-30 | $38.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $39.10M 10-Q · filed 2014-08-11 | |||||
| 2013-03-31 | $953.08K 10-Q · filed 2014-05-12 | ||||||
| 2012-12-31 | -$3.37M 10-K · filed 2015-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |